ENTA
Price
$16.60
Change
+$0.89 (+5.67%)
Updated
Dec 24 closing price
Capitalization
479.12M
46 days until earnings call
Intraday BUY SELL Signals
VRDN
Price
$32.28
Change
+$0.17 (+0.53%)
Updated
Dec 24 closing price
Capitalization
3.08B
70 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ENTA vs VRDN

Header iconENTA vs VRDN Comparison
Open Charts ENTA vs VRDNBanner chart's image
Enanta Pharmaceuticals
Price$16.60
Change+$0.89 (+5.67%)
Volume$292.15K
Capitalization479.12M
Viridian Therapeutics
Price$32.28
Change+$0.17 (+0.53%)
Volume$403.58K
Capitalization3.08B
ENTA vs VRDN Comparison Chart in %
ENTA
Daily Signal:
Gain/Loss:
VRDN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ENTA vs. VRDN commentary
Dec 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ENTA is a StrongBuy and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 25, 2025
Stock price -- (ENTA: $16.60 vs. VRDN: $32.28)
Brand notoriety: ENTA and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ENTA: 73% vs. VRDN: 22%
Market capitalization -- ENTA: $479.12M vs. VRDN: $3.08B
ENTA [@Biotechnology] is valued at $479.12M. VRDN’s [@Biotechnology] market capitalization is $3.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ENTA’s FA Score shows that 1 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • ENTA’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, ENTA is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ENTA’s TA Score shows that 3 TA indicator(s) are bullish while VRDN’s TA Score has 3 bullish TA indicator(s).

  • ENTA’s TA Score: 3 bullish, 4 bearish.
  • VRDN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than VRDN.

Price Growth

ENTA (@Biotechnology) experienced а +16.49% price change this week, while VRDN (@Biotechnology) price change was +0.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

ENTA is expected to report earnings on Feb 09, 2026.

VRDN is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($3.08B) has a higher market cap than ENTA($479M). ENTA YTD gains are higher at: 188.696 vs. VRDN (68.388). ENTA has higher annual earnings (EBITDA): -71.28M vs. VRDN (-298.48M). VRDN has more cash in the bank: 491M vs. ENTA (189M). VRDN has less debt than ENTA: VRDN (21.6M) vs ENTA (57.9M). VRDN has higher revenues than ENTA: VRDN (70.8M) vs ENTA (65.3M).
ENTAVRDNENTA / VRDN
Capitalization479M3.08B16%
EBITDA-71.28M-298.48M24%
Gain YTD188.69668.388276%
P/E RatioN/AN/A-
Revenue65.3M70.8M92%
Total Cash189M491M38%
Total Debt57.9M21.6M268%
FUNDAMENTALS RATINGS
ENTA vs VRDN: Fundamental Ratings
ENTA
VRDN
OUTLOOK RATING
1..100
1776
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
10062
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
3537
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
2550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRDN's Valuation (52) in the Biotechnology industry is somewhat better than the same rating for ENTA (99). This means that VRDN’s stock grew somewhat faster than ENTA’s over the last 12 months.

VRDN's Profit vs Risk Rating (62) in the Biotechnology industry is somewhat better than the same rating for ENTA (100). This means that VRDN’s stock grew somewhat faster than ENTA’s over the last 12 months.

VRDN's SMR Rating (98) in the Biotechnology industry is in the same range as ENTA (98). This means that VRDN’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's Price Growth Rating (35) in the Biotechnology industry is in the same range as VRDN (37). This means that ENTA’s stock grew similarly to VRDN’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for VRDN (100). This means that ENTA’s stock grew significantly faster than VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ENTAVRDN
RSI
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
82%
Bullish Trend 2 days ago
74%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
81%
Declines
ODDS (%)
Bearish Trend 9 days ago
83%
Bearish Trend 8 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
76%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
ENTA
Daily Signal:
Gain/Loss:
VRDN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VVILX28.460.09
+0.32%
Vulcan Value Partners Institutional
PGRCX46.880.09
+0.19%
BNY Mellon Worldwide Growth C
QUAYX79.970.09
+0.11%
AB Small Cap Growth Advisor
FNIAX46.43N/A
N/A
Fidelity Advisor New Insights A
GGSOX16.29N/A
N/A
Grandeur Peak Global Stalwarts Investor

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with MRUS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then MRUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
+5.67%
MRUS - ENTA
50%
Loosely correlated
+0.01%
NEVPF - ENTA
44%
Loosely correlated
N/A
ORKA - ENTA
38%
Loosely correlated
+1.29%
VRDN - ENTA
35%
Loosely correlated
+0.53%
ANAB - ENTA
34%
Loosely correlated
-0.06%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with NUVL. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
+0.53%
NUVL - VRDN
58%
Loosely correlated
+0.89%
XNCR - VRDN
56%
Loosely correlated
-0.13%
CLDX - VRDN
54%
Loosely correlated
+0.94%
SYRE - VRDN
54%
Loosely correlated
-0.54%
RVMD - VRDN
51%
Loosely correlated
+1.15%
More